Sign in
Not yet recruitingNo phase

OM-85 bacterial lysate plus antihistamines for chronic spontaneous urticaria

Looks at OM-85 added to antihistamines in adults with chronic spontaneous urticaria.

Key facts

Who runs it
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Safety of Bacterial Lysate (OM-85) in Combination With Antihistamines for the Treatment of Chronic Spontaneous Urticaria (CSU)
Status
Not yet recruiting
People taking part
132 people, planned
Started
1 May 2026
Expected to end
1 Jun 2027
Type of study
Observational, 2 groups
Record updated
7 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic spontaneous urticaria (long-lasting hives with no clear outside trigger) whose symptoms are not controlled by antihistamines. It compares people taking the bacterial lysate OM-85 with antihistamines against people taking antihistamines alone.

Age
18 to 65 years
Sex
All sexes
Disease stage
Chronic spontaneous urticaria lasting 6 weeks or more. Symptoms still not controlled, with a UAS7 score of 7 or more in the 7 days before the screening and baseline visits.
Earlier treatment
A standard dose of a second-generation H1 antihistamine (for example desloratadine 5 mg, levocetirizine 5 mg) taken regularly for at least 2 weeks before screening. People must keep the same antihistamine and dose during the trial. No steroid tablets or injections, immunosuppressants or antibiotics in the last 4 weeks. No biologics, bacterial lysates or vaccinations in the last 3 months.
Biomarker or test result
UAS7 score (a weekly hives symptom score) of 7 or more.

Main reasons for not taking part

  • Special types of hives, such as physical urticaria, urticarial vasculitis, or swelling from C1 esterase inhibitor deficiency
  • Severe autoimmune disease, such as lupus, rheumatoid arthritis or inflammatory bowel disease
  • History of serious liver, kidney, heart, lung or blood disease, or cancer
  • Allergy to bacterial lysates or their other ingredients
  • Pregnant or breastfeeding, or not planning to use contraception during the trial

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • The participants were fully informed of the purpose, procedure and risks of the study and voluntarily signed the informed consent form
  • Aged 18 to 65 (inclusive), no gender restrictions
  • Meets the CSU diagnostic criteria, with a disease duration of ≥6 weeks
  • Antihistamine resistance: Regular use of a standard dose (as recommended in the package leaflet) of a second-generation H1 antihistamine (e.g. desloratadine 5 mg, levocetirizine 5 mg, etc.) for at least 2 weeks prior to screening, but with symptoms still not effectively controlled. Defined as: a UAS7 score of ≥7 within 7 days prior to the screening visit (V1) and baseline visit (V2)
  • Agree to maintain the type and dose of the baseline antihistamine throughout the trial
  • Agree not to consume any products that may significantly affect the gut microbiota during the trial (such as yoghurt containing probiotics, or probiotic/prebiotic supplements)
  • At the baseline visit, the treatment regimen was clearly defined, and exposure status (OM-85 exposure group or non-exposure group) could be determined based on actual prescriptions and medication records

Who cannot take part

  • Special types of urticaria: These primarily include physical urticaria (such as artificial urticaria, cold contact urticaria and cholinergic urticaria), urticarial vasculitis, and angioedema caused by hereditary or acquired C1 esterase inhibitor deficiency
  • Systemic use of glucocorticoids (oral or injectable) within the four weeks prior to screening
  • Exclude patients who have used immunosuppressants (such as cyclosporine, methotrexate, or Tripterygium wilfordii) within the previous four weeks
  • Exclude patients who have used biologics (such as omazulimab, dupilumab, etc.) within the previous three months
  • Exclude those who have used bacterial lysates (such as Panfuxu or Pidomod) or received vaccinations within the past three months
  • Key exclusion criteria for the microbiome study: use of oral or intravenous antibiotics within the four weeks prior to screening, or continuous use of probiotic supplements for more than one week
  • Patients with severe systemic autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.) may interfere with the assessment of immune mechanisms
  • A history of serious liver, kidney, heart, lung or blood disorders, or malignant tumours
  • Individuals known to be allergic to bacterial lysates and their excipients
  • Other: Participants who have taken part in other clinical trials involving medicinal products within the past 30 days; or where the investigator considers that there is poor compliance, a mental health condition, or any other circumstance rendering the participant unsuitable for the trial
  • Special populations: pregnant or breastfeeding women, or participants of childbearing age who do not intend to use contraception during the trial

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A Prospective Clinical Study on the Efficacy and Safety of Bacterial Lysate (OM-85) Combined with Antihistamines in the Treatment of Chronic Spontaneous Urticaria (CSU): A Single-Centre, Observational, Cohort Study

The 2 groups in the trial

  • Exposure group

    Bacterial lysate capsules + second-generation antihistamines (loratadine tablets, cetirizine hydrochloride tablets, levocetirizine hydrochloride tablets, ebastine tablets, olopatadine hydrochloride tablets, fexofenadine hydrochloride tablets)

  • Non-exposure group

    Second-generation antihistamines (loratadine tablets, cetirizine hydrochloride tablets, levocetirizine hydrochloride tablets, ebastine tablets, olopatadine hydrochloride tablets, fexofenadine hydrochloride tablets)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Clinical Study on the Efficacy and Safety of Bacterial Lysate (OM-85) Combined With Antihistamines in the Treatment of Chronic Spontaneous Urticaria (CSU): A Single-Centre, Observational, Cohort Study
Plain-language title
OM-85 bacterial lysate plus antihistamines for chronic spontaneous urticariaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07557888, who can take part
Record updated
7 May 2026